Tech Moves: Seattle startups hire new execs; board shuffles at Adaptive and Porch geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Codagenix, Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today presented.
Codagenix Presents Positive Phase 1 Data for COVI-VAC Intranasal COVID-19 Vaccine at IDWeek 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
ABC News
Turn on desktop notifications for breaking stories about interest?
OffOn
Phase 1 trials have begun in London for a new nasal vaccine.
• 8 min read
On Location: April 19, 2021
Catch up on the developing stories making headlines.J. Conrad Williams, Jr./Newsday via Getty Images, FILE
LONDON Trials have begun in London for the next generation of COVID-19 vaccines with the first dose for a new nasal vaccine being developed by the U.S. company Codagenix having been administered at a quarantine facility in London, it was announced Monday morning.
“This vaccine is one of the first of the next generation COVID-19 vaccines, it is a single dose, needle free, intranasal, live attenuated COVID-19 virus vaccine.” Cathal Friel, Executive Chairman, of Open Orphan, the company running the trials said in a statement.